CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 701–800 of 1,725
Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects
George, C. A., Sahu, S. U., de Oñate, L., Souza, B. S. D. F., & Wilson, R. C. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0036 · Cited by 19
“26,27 Initiatives in in vivo genome editing targeting T cells include a trial by Excision BioTher-apeutics, which employs an AAV vector with multiplex CRISPR targeting to facilitate the excision of integrated proviral DNA within HIV-infected reservoirs.”
Applications of CRISPR/Cas as a Toolbox for Hepatitis B Virus Detection and Therapeutics
Kumar, A., Combe, E., Mougené, L., Zoulim, F., & Testoni, B. (2024) · Viruses · doi:10.3390/v16101565 · Cited by 19
Sahu, S. U., Castro, M., Muldoon, J. J., Asija, K., Wyman, S. K., Krishnappa, N., de Oñate, L., Eyquem, J., Nguyen, D. N., & Wilson, R. C. (2025) · Nature Protocols · doi:10.1038/s41596-025-01154-8 · Cited by 19
“LNPs hold substantial promise for in vivo use in T cells and HSPCs, having demonstrated clinical success in CRISPR delivery to the liver 40 and recently showing promise for in vivo T cell delivery in preclinical models 41,42 .”
Model‐Informed Drug Development Applications and Opportunities in mRNA ‐ LNP Therapeutics
Zhou, J., Rao, R. P., Shapiro, M. E., Tania, N., Herron, J. C., Musante, C. J., & Hughes, J. H. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3641 · Cited by 16
“33,34 35–37 This has been characterized as a rapid clearance from the plasma and corresponding uptake in the liver, followed by a redistribution from the liver back to the plasma and a subsequent slower clearance through the liver.”
In vivo delivery systems for CRISPR genome editing: Viral and non-viral carriers
Lee, Y., Kim, B., Lee, D., Cheon, S. Y., Lim, S. G., Kim, Y., & Koo, H. (2025) · Applied Physics Reviews · doi:10.1063/5.0228874 · Cited by 13
Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies
Warner, A. L. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2639 · Cited by 13
Therapeutic application of genome editing in dyslipidemia
Whittaker, M. N., & Musunuru, K. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000805 · Cited by 12
Revertant Mosaicism in Genodermatoses: Natural Gene Therapy Right before Your Eyes
van den Akker, P. C., Bolling, M. C., & Pasmooij, A. M. G. (2022) · Biomedicines · doi:10.3390/biomedicines10092118 · Cited by 13
RNA in Therapeutics: CRISPR in the Clinic
Carroll, D. (2022) · Molecules and Cells · doi:10.14348/molcells.2022.0163 · Cited by 14
“Intellia has devised a strategy to reduce TTR production and aggregation by introducing knockout mutations in the gene with Cas9 cleavage (Gillmore et al., 2021).”
CRISPR/Cas9-mediated gene editing. A promising strategy in hematological disorders
Ugalde, L., Fañanas-Baquero, S., Torres-Ruiz, R., Bustamante, O. Q., & Río, P. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2022.11.014 · Cited by 20
Phan, H. T. L., Kim, K., Lee, H., & Seong, J. K. (2023) · Genes · doi:10.3390/genes14020483 · Cited by 17
“Interestingly, Cas9 RNA- and sgRNA-packaged LNPs have been successfully used to treat patients suffering from transthyretin amyloidosis in an ongoing phase 1 clinical research [182].”
BackgroundMicrobiota–Liver Diseases Interactions
Capparelli, R., Cuomo, P., Gentile, A., & Iannelli, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043883 · Cited by 14
“The treatment with CRISPR-Cas editing technology of patients suffering from transthyretin amyloidosis (ATTR) yielded very encouraging results [28].”
BackgroundSocié, P., Benmalek, A., Cauquil, C., Piekarski, E., Kounis, I., Eliahou, L., Rousseau, A., Rouzet, F., Echaniz-Laguna, A., Samuel, D., et al. (2023) · Amyloid: Journal of Protein Folding Disorders · doi:10.1080/13506129.2023.2177986 · Cited by 9
Huang, L., Wang, D., Chen, H., Hu, J., Dai, X., Liu, C., Li, A., Shen, X., Chen, Q., Sun, H., et al. (2023) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2023.03.010 · Cited by 13
Zhao, J.-J., Sun, X., Tian, S.-N., Zhao, Z.-Z., Yin, M., Zhao, M., Zhang, F., Li, S.-A., Yang, Z.-X., Wen, W., et al. (2024) · BMC Genomics · doi:10.1186/s12864-024-10050-6 · Cited by 14
“In addition, in vivo CRISPR-Cas9 editing employing lipid nanoparticles has demonstrated therapeutic efficacy in patients with transthyretin amyloidosis [10].”
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions
Chen, Y. F. F., Aimo, A., Castiglione, V., Chubuchna, O., Morfino, P., Fabiani, I., Buda, G., Emdin, M., & Vergaro, G. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00701-4 · Cited by 14
“The phase 3 HELIOS-B study explored the effects of vutrisiran among patients with ATTR-CA at 30–36 months: 1 3 patients with ATTRv-PN demonstrated that patients well tolerated NTLA-2001 infusion with limited mild adverse events [ 62].”
Exploring the Potential and Advancements of Circular RNA Therapeutics
Wang, L., Wang, L., Dong, C., Liu, J., Cui, G., Gao, S., & Liu, Z. (2025) · Exploration · doi:10.1002/exp.20240044 · Cited by 21
“The direct administration of CRISPR-mRNA enables efficient intrabody gene editing, and a single dose resulted in sustained reduction of serum TTR protein levels for up to 12 months [124].”
Advances in Therapeutic Applications of CRISPR Genome Editing for Spinal Pain Management
Kang, C. Y., Been, K. W., Kang, M. R., Choi, M. S., Kang, R. H., Hur, J. W., & Hur, J. K. (2025) · Neurospine · doi:10.14245/ns.2550462.231 · Cited by 17
Advances in the rational design of ionizable lipids for mRNA therapeutics
Lee, Y., Guo, K., Oh, M., Kim, E., Jeong, Y., Yoon, Y., Choi, Y., Hwang, Y., Byeon, Y., Dong, Y., et al. (2025) · Materials Today · doi:10.1016/j.mattod.2025.07.028 · Cited by 23
Grudzinska‐Goebel, J., Braun, M., Chen, L., Gupta, S., Lohmann, S., Morais, P., Niu, T., Tarcsa, E., Tourdot, S., Youssef, A. S., et al. (2025) · Nucleic Acid Therapeutics · doi:10.1177/21593337251387423 · Cited by 21
“48,86,192,193 In ASOs and siRNA-based therapies without encapsulation, no speci fi c intervention was reported to manage ISR.”
Nanomaterials in gene therapy and genome editing: challenges and emerging directions
Jiang, M., Zhang, K., Wang, Z., Gao, M., Su, S., He, J., Xu, H., Bo, Z., Jiang, Z., Zhang, C., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03895-w · Cited by 17
Mehnath, S. (2025) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaf127 · Cited by 15
Monitoring biological effects of somatic cell genome editing
Freedman, B., Bulte, J. W. M., Conklin, B. R., Judge, L. M., Dwinell, M. R., Geurts, A. M., Sitton, M. J., Mahajan, V., Kiani, S., Gersbach, C. A., et al. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-025-00916-0 · Cited by 16
Targeted therapy for pulmonary alveolar proteinosis: the time is now
Bonella, F., & Borie, R. (2022) · European Respiratory Journal · doi:10.1183/13993003.02971-2021 · Cited by 11
The history, use, and challenges of therapeutic somatic cell and germline gene editing
Ryu, J., Adashi, E. Y., & Hennebold, J. D. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.02.040 · Cited by 13
Adair, B., Korecki, A. J., Djaksigulova, D., Wagner, P. K., Chiu, N. Y., Lam, S. L., Lengyell, T. C., Leavitt, B. R., & Simpson, E. M. (2023) · Ophthalmology and Therapy · doi:10.1007/s40123-023-00729-6 · Cited by 12
Taharabaru, T., Kihara, T., Onodera, R., Kogo, T., Wen, Y., Li, J., Motoyama, K., & Higashi, T. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100690 · Cited by 11
“As future efforts, we should study the therapeutic potential of 5G/genome-editing RNP system for the treatment of genetic diseases which can be cured by single-gene knockout, such as sickle cell disease [40], transthyretin amyloidosis [41], and familial hypercholesterolemia [42].”
BackgroundZhang, Y., Zhao, G., Liu, J., Zhang, H., Wang, Y., Luo, Y., Lu, Z.-D., Du, X., Shen, S., Du, J., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101992 · Cited by 12
The New Frontiers of Gene Therapy and Gene Editing in Inflammatory Diseases
Romano, A. P. M., & Mortellaro, A. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.210 · Cited by 13
Challenges and progress related to gene editing in rare skin diseases
Hofbauer, J. P., Guttmann‐Gruber, C., Wally, V., Sharma, A. K., Gratz, I. K., & Koller, U. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115294 · Cited by 18
Therapeutic applications of cell engineering using mRNA technology
He, Y., Johnston, A. P. R., & Pouton, C. W. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.07.012 · Cited by 14
The future of complement therapeutics
Kolev, M. V., Rao, K. N., Yeh, M. W., Parikh, A., & Deschatelets, P. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00161 · Cited by 15
Li, L., Luo, M., Zhou, L., Wang, Y., Jiao, Y., Wang, C., Gong, C., Cen, X., & Yao, S. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125282 · Cited by 13
Cardiac amyloidosis: Innovations in diagnosis and treatment
Castiglione, V., Montuoro, S., Orlando, G., Aimo, A., Vergaro, G., & Emdin, M. (2025) · European Heart Journal, Supplement · doi:10.1093/eurheartjsupp/suae111 · Cited by 12
Precise measurement of CRISPR genome editing outcomes through single-cell DNA sequencing
Kalter, N., Gulati, S., Rosenberg, M., Ayaz, Q., Nguyen, J., Wang, S., Schroeder, B., Li, C.-Y., & Hendel, A. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101449 · Cited by 18
Shining light on CRISPR/Cas9 therapeutics for inherited retinal diseases
Geiger, A., Kennedy, J. G., Staker, L. G., Wensel, T. G., Casson, R. J., & Thomas, P. Q. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101376 · Cited by 11
Ye, B., Hu, Y., ZHANG, M., & Huang, H. (2022) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2022-0047 · Cited by 20
Innovative cancer nanomedicine based on immunology, gene editing, intracellular trafficking control
Yamada, Y., Sato, Y., Nakamura, T., & Harashima, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.033 · Cited by 11
Lee, A. B. C., Tan, M. H., & Chai, C. L. L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.06.006 · Cited by 13
NTLA-2001: opening a new era for gene therapy
Cui, T., Li, B., & Li, W. (2022) · Life Medicine · doi:10.1093/lifemedi/lnac036 · Cited by 11
Rare and undiagnosed diseases: From disease-causing gene identification to mechanism elucidation
Wang, G., Xu, Y., Wang, Q., Chai, Y., Sun, X., Yang, F., Zhang, J., Wu, M., Liao, X., Yu, X., et al. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.09.002 · Cited by 15
“A recent CRISPR-based in vivo therapy has been shown to effectively reduce the serum concentration of misfolded transthyretin protein, thereby alleviating the symptoms of ATTR amyloidosis [101] .”
BackgroundSelf-citationCRISPR/Cas systems usher in a new era of disease treatment and diagnosis
Li, R., Wang, Q., She, K., Lu, F., & Yang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00095-y · Cited by 14
Development of novel therapeutics for all individuals with CF (the future goes on)
Amaral, M. D., & Harrison, P. T. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.10.007 · Cited by 14
Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy
Nuvolone, M., Girelli, M., & Merlini, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416145 · Cited by 13
“Noteworthy, administration of NTLA-2001 led to dose-dependent decreases in serum TTR protein concentrations (up to 87%) and was associated with only mild adverse events [147].”
BackgroundInfluentialLekstrom-Himes, J. A., Brooks, P. J., Koeberl, D. D., Brower, A., Goldenberg, A. J., Green, R. C., Morris, J. A., Orsini, J. J., Yu, T. W., & Augustine, E. F. (2023) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.32031 · Cited by 14
Gene Editing as the Future of Cardiac Amyloidosis Therapeutics
Sethi, Y., Mahtani, A. U., Khehra, N., Padda, I., Patel, N., Sebastian, S. A., Malhi, G., Kaiwan, O., Saith, S. E., & Johal, G. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101741 · Cited by 11
Chen, L., Zhang, N., Huang, Y., Zhang, Q., Fang, Y., Fu, J., Yuan, Y., Chen, L., Chen, X., Xu, Z., et al. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10583-5 · Cited by 12
Han, Z., Zhou, D., Wang, J., Jiang, B., & Liu, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188677 · Cited by 14
Translational potential of base-editing tools for gene therapy of monogenic diseases
Reshetnikov, V. V., Chirinskaite, A. V., Sopova, J. V., Ivanov, R. A., & Леонова, Е. И. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.942440 · Cited by 14
Yang, J., Sun, J., Zhu, J., Du, Y., Tan, Y., Wei, L., Zhao, Y., Hou, Q., Zhang, Y., Sun, Z., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.22.489232 · Cited by 11
“mRNA-based gene editing project for the treatment of Transthyretin Amyloidosis, by delivering Cas9 mRNA and gRNA to hepatocytes (32).”
BackgroundTeter, B., Campagna, J. J., Zhu, C., McAuley, G. E., Spilman, P. R., Kohn, D. B., & John, V. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.23.590784 · Cited by 13
Dipalo, L. L., Mikkelsen, J. G., Gijsbers, R., & Carlon, M. S. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.258 · Cited by 12
Gene Editing Applications as Future Cardiovascular Therapies
Tadokoro, T., Olson, E. N., & Liu, N. (2025) · Annual Review of Genetics · doi:10.1146/annurev-genet-011725-094039 · Cited by 11
“Importantly, the delivery of LNPs has succeeded in clinical trials (41).”
Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors
Wang, S., Xu, X., Viitala, T., Shu, Y., & Zhang, H. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102737 · Cited by 15
“The natural tendency of LNPs to accumulate in the liver has sparked the interest of current clinical studies for LNP-mediated delivery of mRNA forms of CRISPR-Cas9 mainly for liver-related diseases, such as the NTLA-2001 trial 48 and the VERVE-101 trial.”
mRNA therapeutics beyond vaccines: dosing precision challenges and clinical translation framework
Niazi, S. K. (2026) · RSC Pharmaceutics · doi:10.1039/d5pm00159e · Cited by 19
Measurement and clinical interpretation of CRISPR off-targets
Stewart, A. A., Ahrens‐Nicklas, R. C., Tsai, S. Q., Musunuru, K., Giannikopoulos, P., & Clelland, C. D. (2025) · Nature Genetics · doi:10.1038/s41588-025-02428-3 · Cited by 20
“Although editing was observed in bulk ovarian tissue 9,12 , it was not observed in progeny from gene-edited female mice 10,12 , confirming a lack of germline transmission of the introduced edits.”
Therapeutic applications of CRISPR-Cas9 gene editing
Bharti, A., & Mudge, J. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1724291 · Cited by 17
Zhao, R., Wang, C., 李佳楣, Liao, Y., Huang, C., Hu, T., Zhang, H., & Zhang, W. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00456-x · Cited by 18
“…of Cas9 mRNA and a TTR-targeting single-guide RNA encapsulated within LNPs, demonstrated significant dose-dependent decreases in levels of serum TTR following a single administration among patients with hereditary ATTR amyloidosis with polyneuropathy; the majority of adverse events were mild [61].”
InfluentialCRISPR/Cas-Based Gene Editing Strategies for DOCK8 Immunodeficiency Syndrome
Ravendran, S., Hernández, S. S., König, S., & Bak, R. O. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.793010 · Cited by 12
CRISPR editing in the lung with novel lipids
Elia, U., Kon, E., & Peer, D. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01744-5 · Cited by 10
Cardiac amyloidosis: evolving pathogenesis, multimodal diagnostics, and principles of treatment
Medarametla, G. D., Kahlon, R. S., Mahitha, L., Shariff, S., Vakkalagadda, N. P., Chopra, H., Kamal, M. A., Patel, N., Sethi, Y., & Kaka, N. (2023) · EXCLI journal · doi:10.17179/excli2023-6284 · Cited by 15
Non-viral delivery of RNA for therapeutic T cell engineering
Berdecka, D., Smedt, S. C. D., Vos, W. H. D., & Braeckmans, K. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115215 · Cited by 15
Efficient Gene Editing for Heart Disease via ELIP-Based CRISPR Delivery System
Yin, X., Harmancey, R., Frierson, B., Wu, J. G., Moody, M. R., McPherson, D. D., & Huang, S. L. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030343 · Cited by 12
“…vesicle and the release of this cargo at target tissue sites. a safer alternative, known for their ability to accommodate larger payloads [1,3,13,29–31 Through the integration of positively charged lipids, we’ve engineered acoustically responsive liposomes, facilitating the incorporation of…”
BackgroundCRISPR/Cas9 Gene Editing: A Novel Approach Towards Alzheimer's Disease Treatment
Tripathi, S., Sharma, Y., Rane, R. A., & Kumar, D. (2024) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273283786240408034408 · Cited by 12
Tonetto, E., Cucci, A., Follenzi, A., Bernardi, F., Pinotti, M., & Balestra, D. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.04.020 · Cited by 11
CRISPR-Cas9 for selective targeting of somatic mutations in pancreatic cancers
Teh, S. S. K., Bowland, K., Halper‐Stromberg, E., Kotwal, A., Bennett, A., Skaist, A. M., Tang, J., Cai, F., Macoretta, A., Liang, H., et al. (2024) · NAR Cancer · doi:10.1093/narcan/zcae028 · Cited by 14
“Currently, CRISPR - Cas9 gene editing therapies approved or under clinical trials work by either disrupting the expression of an existing gene ( 8 , 10 , 11 ), correcting mutation (NCT04774536), or for engineering CAR-T cells ( 12 ).”
BackgroundEvolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis
Ioannou, A. (2024) · Heart International · doi:10.17925/hi.2024.18.1.5 · Cited by 15
Transthyretin Orchestrates Vitamin B12–Induced Stress Resilience
Stein, G., Aly, J. S., Manzolillo, A., Lange, L. D., Riege, K., Hussain, I., Heller, E. A., Cubillos, S., Ernst, T., Hübner, C. A., et al. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.07.009 · Cited by 11
“In this context, TTR stands as the fi rst gene edited by CRISPR technology in vivo in humans (21).”
Cianci, V., Cianci, A., Sapienza, D., Cracò, A., Germanà, A., Ieni, A., Gualniera, P., Asmundo, A., & Mondello, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175140 · Cited by 16
Onuma, H., Shimizu, R., Suzuki, Y., Sato, M., Harashima, H., & Sato, Y. (2024) · iScience · doi:10.1016/j.isci.2024.110928 · Cited by 12
Lipid-based Non-viral Vector: Promising Approach for Gene Delivery
Panday, A., Dixena, B., Jain, N. S., & Jain, A. K. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128324084240828084904 · Cited by 12
Unveiling the Future of Cardiac Care: A Review of Gene Therapy in Cardiomyopathies
Venturiello, D., Tiberi, P. G., Perulli, F., Nardoianni, G., Guida, L., Barsali, C., Terrone, C., Cianca, A., Lustri, C., Sclafani, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313147 · Cited by 14
Dual pH-responsive CRISPR/Cas9 ribonucleoprotein xenopeptide complexes for genome editing
Luo, X., Germer, J., Burghardt, T., Grau, M., Lin, Y., Höhn, M., Lächelt, U., & Wagner, E. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106983 · Cited by 13
Escobar, H., Francescantonio, S. D., Smirnova, J., Graf, R., Müthel, S., Marg, A., Zhogov, A., Krishna, S., Metzler, E., Petkova, M. V., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55086-0 · Cited by 14
Advancing Precision Medicine: Recent Innovations in Gene Editing Technologies
Abhijith, K., & Thangavel, S. (2025) · Advanced Science · doi:10.1002/advs.202410237 · Cited by 15
Hanlon, M. B., Shohet, J. M., & Wolfe, S. A. (2025) · Nature Communications · doi:10.1038/s41467-025-60160-2 · Cited by 14
“21, 22).”
Vo, Q. D. (2025) · PLoS ONE · doi:10.1371/journal.pone.0325330 · Cited by 14
“Similarly, first in vivo CRISPR clinical trial targeted TTR using lipid nanoparticles (LNPs) to deliver Cas9 to the liver, resulting in an 87% reduction in circulating mutant TTR protein [94].”
Ferreira, D. A., McMillan, N. A. J., & Idris, A. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113782 · Cited by 10
Africa must participate in finding a gene therapy cure for sickle-cell disease
Moshi, G. B., Sheehan, V., & Makani, J. (2022) · Nature Medicine · doi:10.1038/s41591-022-02033-5 · Cited by 10
Puppulin, L., Ishikawa, J., Sumino, A., Marchesi, A. S., Flechsig, H., Umeda, K., Kodera, N., Nishimasu, H., & Shibata, M. (2023) · ACS Nano · doi:10.1021/acsnano.2c10709 · Cited by 11
CRISPR-Analytics (CRISPR-A): A platform for precise analytics and simulations for gene editing
Sanvicente-García, M., García-Valiente, A., Jouide, S., Jaraba-Wallace, J., Bautista, È., Escobosa, M., Sánchez-Mejías, A., & Güell, M. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011137 · Cited by 14
“Nowadays, it is even on the verge of becoming a therapeutic reality in vivo [4].”
BackgroundLiu, Q., Chen, Y., Hu, S., Liu, W., Xie, D., Yang, X., Huang, W., Liu, S., Chen, X., Liu, H., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.055 · Cited by 12
CRISPR-Cas: ‘The Multipurpose Molecular Tool’ for Gene Therapy and Diagnosis
Sauvagère, S., & Siatka, C. (2023) · Genes · doi:10.3390/genes14081542 · Cited by 14
“It is then a question of evaluating the tolerance of the treatment, determining the best-tolerated dose, and studying its effectiveness regarding functional criteria (through tests of mobility, visual acuity, sensitivity to contrasts, color vision, microperimetry, sensitivity retina evaluated with the full-field light…”
MethodA Step Forward in Solving Amyloidosis
Merlini, G. (2023) · New England Journal of Medicine · doi:10.1056/nejme2309308 · Cited by 10
Landmark CRISPR trial shows promise against deadly disease
Ledford, H. K. (2021) · Nature · doi:10.1038/d41586-021-01776-4 · Cited by 10
In vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges
Cantore, A., Fraldi, A., Meneghini, V., & Gritti, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.774618 · Cited by 17
“Systemic administration of LNP delivering CRISPR/Cas9 RNA to the liver resulted in efficient disruption of TTR gene and subsequent reduction of the toxic misfolded TTR amyloid in 6 affected patients (22).”
BackgroundDeveloping Therapy for Transthyretin Amyloidosis
Campbell, C. M., Zhang, K. W., Lenihan, D. J., & Witteles, R. M. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.01.002 · Cited by 11
Vegezzi, E., Cortese, A., Bergsland, N., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11336-z · Cited by 10
“Moreover, other treatment options are underway [6].”
Dugo, K., Bruno, F., Sturiale, V., Brancato, D., Saccone, S., & Federico, C. (2022) · Biomedicines · doi:10.3390/biomedicines10102394 · Cited by 13
“This dose-dependent reduction varied from 80% to 96% [77].”
BackgroundEmerging trends in gene and cell therapy: CRISPR in DNA editing and beyond
Ji, R., Chen, Q., & Zhang, Y. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102459 · Cited by 19
“LNP-based delivery of Cas9 mRNA and sgRNA targeting TTR achieves sustained serum TTR reduction after a single dose, 173,174 with phase III trials underway.”
Marei, H. E. S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05590-1 · Cited by 15
“Preclinical investigations and initial clinical experiences with CNS-targeted ASOs and AAV-mediated gene regulation establish a basis for tackling these challenges through comprehensive pharmacological assessment, biodistribution analysis, and extended surveillance [53, 56, 59].”
Programmable lipid nanoparticles for RNA therapeutics: Design principles and clinical translation
Talemi, M. N., Farani, M. R., Eskandani, N. A., Mirzaee, D., Alipourfard, I., & Huh, Y. S. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102774 · Cited by 30
“…an sgRNA against TTR: a single intravenous dose produced rapid, deep, and durable reductions in circulating transthyretin in patients with hereditary transthyretin (hATTR), establishing clinical feasibility for liver-tropic LNP delivery of CRISPR and a therapeutic window for transient dosing [131].”
The mRNA-Based Innovative Strategy: Progress and Challenges
Zhou, H., Wei, D., Chen, Z., Chen, H., Dong, C., Cai, W., Wang, J., Liu, X., Li, Y., Yang, Y., et al. (2026) · Nano-Micro Letters · doi:10.1007/s40820-025-01906-x · Cited by 24
“An early report on the treatment of Transthyretin amyloidosis by LNP encapsulating Cas9 mRNA and transthyretin (TTR)-targeted sgRNA has already entered the third clinical phase (NTLA-2001), which was the first in vivo CRISPR gene editing therapy approved for advanced clinical development [21].”
Tian, Z., Wang, X., Chatterjee, S., Miller, W., Guerrero, E. D., Sung, Y., Benitez, A. P., Dilliard, S. A., Bian, X., Vaidya, A., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01615-9 · Cited by 14
Saini, A., Li, S., Wang, Z., Plebanski, M., & Ju, Y. (2026) · ACS Nano · doi:10.1021/acsnano.6c00334 · Cited by 17
Toma, L., Barbălată, T., Sanda, G. M., Niculescu, L. S., Sima, A. V., & Stancu, C. S. (2021) · Biomolecules · doi:10.3390/biom11121769 · Cited by 10
“Preliminary results of clinical studies show that CRISPR/Cas9 technology has been successfully used to treat neurological disorders [52].”
CRISPR‐Cas Biochemistry and CRISPR‐Based Molecular Diagnostics
Weng, Z., You, Z., Yang, J., Mohammad, N., Lin, M., Wei, Q., Gao, X., & Zhang, Y. (2023) · Angewandte Chemie · doi:10.1002/ange.202214987 · Cited by 12
CRISPR–Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer
Smith, D. J., Lunj, S., Adamson, A. D., Nagarajan, S., Smith, T., Reeves, K. J., Hoskin, P., & Choudhury, A. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00901-y · Cited by 13
“The liver, for example, has proven to be a targetable organ via lipid nanoparticle-based delivery systems for the treatment of transthyretin amyloidosis 94 .”
Janns, J. H., & Mikkelsen, J. G. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.105 · Cited by 10
“22,23 Notably, this technology also supports incorporation of Cas9/sgRNA RNPs, 24 although standard production and use has focus primarily on mRNA/ sgRNA delivery.”
Mechanisms of damage and therapies for cardiac amyloidosis: a role for inflammation?
Bellofatto, I. A., Nikolaou, P., Andreadou, I., Canepa, M., Carbone, F., Ghigo, A., Heusch, G., Kleinbongard, P., Maack, C., Podesser, B. K., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02522-2 · Cited by 10
“[142] Other targeted therapies to reduce the amyloid precursor protein production include CRISPR/Cas9 gene-editing therapy with NTLA-2001 which reduced TTR protein levels through targeted deletion of its gene [143].”
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



